CompletedNot Applicable

Role of Prohepcidin in Uremic Patients

Turkey (Türkiye)25 participantsStarted 2010-01

Plain-language summary

The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * hemodialysis and peritoneal dialysis patients who had been on dialysis therapy for more than 3 months, * age between 18-80 years, * patients with creatinine clearance between 15-30 ml/min. Exclusion Criteria: * age less than 18 or more than 80, * diabetic patients, * current active infectious or inflammatory disease.

What they're measuring

prohepcidin level

Timeframe: Six months

Trial details

NCT IDNCT01735773

SponsorHaseki Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-03

View on ClinicalTrials.gov More Inflammation trials